(Adnkronos) - In questo numero:
Farmaceutica: le Fab 13 italiane trainano l’economia del Paese
Esperti, ‘con cittadini responsabili della propria salute si riduce impatto malattie cardiovascolari’
Miastenia grave: studio, 'oltre 1 paziente su 10 costretto a rinunciare al lavoro’
E ancora
Emicrania, terapie efficaci ma serve inserimento in piano cronicità
In un anno dispensati in farmacia oltre 2milioni di antidiabetici
Golotta di AbbVie, siamo molto impegnati nella ricerca di cure per le malattie reumatologiche e non solo. In sviluppo Jak inibitore per Les
Lipoproteina (a) fattore determinante per rischio cardiovascolare
Ok di Aifa a rimborsabilità tirzepatide per controllo diabete di tipo 2
Al ministero dell’Istruzione e del merito i risultati del progetto Nutripiatto, l’educazione nutrizionale per bambini
Farmaceutica: le Fab 13 italiane trainano l’economia del Paese
Esperti, ‘con cittadini responsabili della propria salute si riduce impatto malattie cardiovascolari’
Miastenia grave: studio, 'oltre 1 paziente su 10 costretto a rinunciare al lavoro’
E ancora
Emicrania, terapie efficaci ma serve inserimento in piano cronicità
In un anno dispensati in farmacia oltre 2milioni di antidiabetici
Golotta di AbbVie, siamo molto impegnati nella ricerca di cure per le malattie reumatologiche e non solo. In sviluppo Jak inibitore per Les
Lipoproteina (a) fattore determinante per rischio cardiovascolare
Ok di Aifa a rimborsabilità tirzepatide per controllo diabete di tipo 2
Al ministero dell’Istruzione e del merito i risultati del progetto Nutripiatto, l’educazione nutrizionale per bambini
Category
🗞
NewsTranscript
00:00In this number, pharmaceuticals, the 13 Italian FABs, draw the economy of the country.
00:16Experts with citizens responsible for their health reduce the impact of cardiovascular diseases.
00:23In a year, more than 2 million anti-diabetics were dispensed in pharmacies.
00:38We are very committed to the research of cures for rheumatological diseases and not only.
00:45In development, Jack inhibitor for LES.
00:48Lipoprotein A, a determining factor for cardiovascular risk.
00:52Occay de Haifa has Tirsepatide reimbursability for type 2 diabetes control.
00:58To the Ministry of Education of Merit, the results of the NutriPiatto project, nutritional education for children.
01:09The Italian pharmaceutical industry stands out as one of the leading sectors of Made in Italy.
01:15The 13 FABs, the multinational historical capital of the pharmaceutical sector,
01:20confirm their centrality in innovation, research and economic growth of the country.
01:25This is evident from the report presented by the Edison Foundation in Milan,
01:29with which the performance on the domestic and foreign market and the impact on the country system of the 13 FABs were analyzed.
01:36Attracting tricolor pharmaceuticals is above all the export,
01:40but also the acquisition of foreign companies and the development of products beyond national borders.
01:45The foreign market accounts for about 70% of the activity of these companies,
01:54while the Italian market is unfortunately very blocked by administrative prices
01:58and allows them a much more limited development.
02:01Research and development is very important.
02:04There is more than 1 billion euros of investment in research and development by these 13 Italian capital companies
02:12and they certainly deserve more attention from the public opinion,
02:16which often tends to see the pharmaceutical industry as a sector that earns a lot
02:22thanks to large multinational groups.
02:24Instead, we have 13 great Italian protagonists
02:27who make enormous efforts to be able to compete with world groups
02:31and who invest a lot in our country in research, production, employment and staff training.
02:38From Italy, these 13 pharmaceutical companies have also been able to assert themselves globally.
02:43For competitiveness on international markets, however, it is crucial to work as a system.
02:48We keep the heart and mind of our activities here,
02:55we continue to invest.
02:57In terms of research and development, our sector, in particular Italian companies,
03:01make almost 50% of the investment in innovation in Italy.
03:05It is an incredible thing.
03:07In order to be able to do this, you really need to be aware and work as a system.
03:14What we need is stability.
03:18On this occasion, the institutions have also been discussed, as explained by Sergio Dompe.
03:24We do not ask for economic resources,
03:27we ask for legislation that takes into account the commitment and investments
03:34that are made in research on innovation and production in Italy,
03:38which reward export, which reward taxation in our country and research investment.
03:45A theme for everyone, that of access to the data of our national health service,
03:50which can be one of the elements of competitiveness of our system.
04:00224,000 deaths a year, about 600 a day.
04:04In Italy, cardiovascular diseases are real and their own silent killers.
04:08Through the dissemination of knowledge of risks and adequate prevention,
04:12many lives could be saved.
04:14This and much more was discussed at the event dedicated to cardiologists,
04:18Voices for Silencing, organized by Novartis San Milano on March 7 and 8.
04:23Education, education, education at all levels, starting from schools.
04:29That is, even children from the beginning must be educated to this concept
04:36of being responsible for their own health.
04:39The Italian Foundation for the Heart has as its mission to educate civil society
04:49precisely to try, as far as possible, that people become patients as late as possible.
04:57Cardiovascular diseases are the first cause of death, hospitalization and disability,
05:03with a huge impact on the social level and on the national health system.
05:08Two years ago, at the beginning of the legislature, we opened the Intergroup
05:11with the intention of emphasizing more and more the needs of patients.
05:17The main goal of the Intergroup is to emphasize the request to the Ministry of Health
05:22of a practical table in which we talk about cardiovascular diseases on a national level.
05:27The contribution of scientific research is essential to identify the risk factors
05:32that contribute to cardiovascular diseases.
05:35In the cardiovascular area, our contribution is important in the research of those cardiovascular risk factors
05:43that contribute to the pathologies that today represent one of the main causes of death and morbidity.
05:51And also thanks to the new discoveries, such as the high levels of lipoprotein A,
05:58the identification of new risk factors that somehow contribute to the genesis of these cardiovascular pathologies.
06:12Myasthenia is a rare, autoimmune and chronic disease that affects about 17,000 people in Italy.
06:18To highlight the profound social and productive impact of the disease on patients,
06:23family members and caregivers, the first study was conducted in Real World on a global scale, MyRealWorldMG.
06:30Promoted by the Association of Patients and supported by Argenix,
06:33the study analyzed the data of more than 2,000 patients, with a large participation from Italy.
06:39What came out is that in reality this disease has a very significant impact on the daily life of patients,
06:48about 36% of the patients have to reduce their work activities, with a consequent economic loss.
07:06And the other aspect is that there is also a large involvement of caregivers, which are usually 95% family members.
07:20Therefore, the economic losses of both patients and caregivers are added up.
07:27It has been estimated that in Italy we have had a total reduction of 11,000 euros per year per family,
07:37and that the vast majority of this loss is linked to a net loss of the patient and then also of the caregivers.
07:46The photograph taken by the study highlights the difficulties that people who live with this pathology face,
07:52mainly because of the symptoms it carries.
07:55It is a disease characterized by muscle fatigue, that is, the symptoms worsen with effort and improve with rest.
08:03It is a disease that can involve several muscle districts, it is a heterogeneous disease,
08:10it can involve the extraocular muscles, giving rise to diplopia, double vision, palpebral ptosis,
08:17the muscles that are important for phonation, chewing, therefore giving difficulty in speaking, chewing, but also in swallowing.
08:24Or it can give fatigue to the arteries.
08:27In the most severe event, when the muscles are involved in the respiratory tract,
08:33in this case the patient can go into respiratory insufficiency and may require mechanical ventilation support and intensive care.
08:41Combining the results of this study with those of the ADAPT study, the most extensive conducted on patients with serious myasthenia,
08:47Arginix has presented a new publication in Milan,
08:51with which it stands out as the new therapies, among which Gartigi Mod Alpha, developed by Arginix,
08:57in addition to being clinically effective, can reduce the loss of productivity and improve quality of life.
09:03Why do we make this commitment?
09:05On the one hand, they are therapeutic areas with a clinical need that is still unsatisfied,
09:09and where pharmacological innovation has been lacking for several years.
09:13On the other hand, they are those areas where the social impact of the disease is extremely high.
09:18We sometimes make the methodological mistake of thinking that in these diseases the relationship is one-to-one between disease and disease,
09:25but the numbers show how the social impact on the caregiver, on the relatives of these diseases, is much higher.
09:32So from here also our commitment is to try to improve the quality of life, not only of the patient, but also of the relatives.
09:37What is myasthenia?
09:42Myasthenia is the first cause of disability among young women and a source of enormous costs for the national health service.
09:48The intense and pulsating headache, which is often accompanied by nausea, vomiting,
09:52increased sensitivity to light, sounds, noises, odors and fatigue,
09:56compromises the quality of life of about 6 million people in Italy, two-thirds of whom of female sex.
10:02Of the new treatment opportunities, represented above all by monoclonal antibodies,
10:07of the importance that the pathology is recognized as a chronic disease and inserted in the national plan on chronicity,
10:13and of the new guidelines defined by the international scientific community,
10:17we spoke at the event Empatia, Empowerment and Micrania,
10:21Vivere la Vita, organized in Rome by Organon Italia.
10:25We will have a list of drugs, with comments from experts,
10:29so that it goes alongside the other guidelines.
10:32The fundamental intention is to unify as much as possible the approach to subjects with myasthenia around the world,
10:41not only in Italy, not only in the different countries.
10:44We have many drugs and our idea would be to make these drugs available as much as possible
10:49to all people who suffer from this disease, because it is disabling,
10:53because these drugs are effective, because especially the new ones are very well tolerated,
10:59so they do not need monitoring, they do not create toxicity,
11:03and so this was a first step.
11:05A second step we have taken is to decline the effectiveness of drugs in practical recommendations.
11:12The effectiveness, tolerability and safety of the use of monoclonal antibodies in myocardial patients
11:18has been confirmed in clinical practice with results higher than those recorded during the trials.
11:23The real-life evidence that has happened in recent years, which have become copious,
11:28and which represent the results of the clinical practice that we do daily in our ambulatories with our patients,
11:35have even increased the results in terms of effectiveness, quality of life, disability in patients treated with monoclonal antibodies.
11:46To deal with hemicrania, a holistic approach is therefore required,
11:49which includes care and prevention through the tempestuous use of new therapies
11:54and provides a rapid multidisciplinary care of the patient.
11:58It becomes important, as has been reiterated in recent years,
12:02to go and define integrated paths, even organizational models,
12:07related to the care and early diagnosis of patients affected by hemicrania,
12:12because this is the only possible strategy that can help us to classify different types of patients,
12:18to understand which of these patients needs more well-defined care,
12:24or some innovative technologies, also in the pharmacological field,
12:28in such a way that the health level of these patients improves,
12:33but at the same time costs are reduced.
12:42A more sustainable health system, without additional costs for citizens
12:46and with concrete advantages for all involved actors,
12:50demonstrating that innovating does not only mean improving services, but also optimizing public resources.
12:56This is the result of the new way of distributing drugs,
12:59which has transferred the dispensation of some antidiabetics from hospitals to local pharmacies.
13:04A year after the introduction of the regulation,
13:07the Ministry of Health has traced the balance of the impact of this measure on public spending
13:12and on access to care for citizens.
13:14During the event, accessible drugs, balance and prospects,
13:18a year after the regulation, promoted by the Deputy Secretary of Health, Marcello Gemmato.
13:22We have moved a first class of drugs, glyptine, which are antidiabetic drugs,
13:28and even, instead of having a higher expense,
13:32the AIFA certifies that we have saved 9.7 million euros.
13:37So, better access for the citizen, better compliance, therapeutic adherence and care,
13:45savings for the state coffers, it seems to me an excellent result.
13:49From this regulation, then, the National Health Service has saved about 13% of costs
13:55a year after its introduction.
13:57By the end of the year, there is an increase of about 600 million euros compared to conventional pharmaceutical spending.
14:04The impact is overall positive.
14:06Based on these results, the table of monitoring of the Ministry of Health
14:12has given an order to the Italian Pharmaceutical Agency
14:15to proceed with the assessment by March 30 of this year
14:21of a new therapeutic category that can be somehow considered
14:28for the transfer, the reclassification from PHT to A.
14:33According to President FISM, Loretto Gesualdo,
14:36the accessibility to the drug can be moved more directly to the conventional
14:41to allow the citizen to have a greater proximity.
14:44This means a better quality of life for the patient and also his caregiver.
14:51This will certainly lead to a better sustainability of our national health system,
14:58reducing direct and indirect costs.
15:01We have seen the results of the first year, they are very encouraging,
15:05we are on the right track, we do not give up, we become a system,
15:10we go from a silo system to a horizontal system.
15:14Although there are still margins of further practicability,
15:17both pharmacists and citizens have expressed a high level of satisfaction
15:21for the implementation of such measures.
15:24From the point of view of the citizens, because it has guaranteed
15:27a much easier access to the drug, much closer,
15:31and because it has guaranteed more assistance continuity,
15:35therefore from the point of view of the health service, of public health,
15:39also adherence to the cures, because it is guaranteed the possibility of dialogue
15:44also with the pharmacist, which we know is an important element
15:49in the relationship of trust that is created between citizen and pharmacy,
15:53in particular in the redesign of the pharmacy of services.
16:02Improving the standards of care and clinical results for patients
16:06who suffer from rheumatological diseases and not only.
16:09With these objectives, AbbVie has focused attention on its inhibitor,
16:13Upadacetinib.
16:15This oral therapy, authorized for other autoimmune diseases,
16:18is already available in Italy and is also being studied for the treatment
16:22of a complex disease such as lupus erythematosus systemic.
16:25But where does the commitment of this pharmaceutical company for LESS come from?
16:29We asked Caterina Golotta, Director of AbbVie Italy.
16:33AbbVie is an ultraventricular experience in rheumatology
16:36and in this therapeutic area it brings the approach of improving the standards of care
16:42and improving the results for patients who suffer from rheumatological diseases.
16:49Specifically, lupus erythematosus systemic, or LESS,
16:53is an extremely complex autoimmune disease characterized by the production
16:58of auto-antibodies that can affect in a varied and heterogeneous way
17:04various organs and systems.
17:06The pulmonary system, the skeletal muscle system, the acute system
17:10and the central nervous system.
17:12Clearly, the symptoms vary depending on the type of narrow organ involved.
17:18It has an extremely unpredictable chronic course.
17:21Precisely for this reason, the unsatisfied need is very strong
17:26and AbbVie is committed to developing a possible further tool for doctors
17:33to respond to the needs of patients who suffer from this pathology.
17:38Specifically, our inhibitor of JAK, lupatacitinib,
17:43is currently undergoing clinical experimentation in this context.
17:47And what is this therapy specifically about?
17:49On which pathologies has it shown to act positively?
17:52Lupatacitinib is our inhibitor of JAK and is the result of AbbVie's effort,
17:56research and internal development.
17:58It is an irreversible selective inhibitor of JAK kinase
18:02and is currently approved and reimbursed in a series of immunological pathologies.
18:07Rheumatoid arthritis, architosaccharide spondylitis and psoriasis arthritis,
18:12cirrhosis colitis and atopic dermatitis.
18:15We remain confident in the results of the molecule
18:20in the development program of systemic erythematosus lupus.
18:23Among other things, lupatacitinib is currently being studied
18:27in two other pathologies in the immunological field,
18:31vitiligin and alopecia areata.
18:33But what does AbbVie do?
18:36AbbVie is a global biopharmaceutical company based on research,
18:40focused on patients and strongly devoted to innovation and research and development.
18:46With the aim of having a significant impact on the lives of patients
18:51and focusing on therapeutic areas of which it has great experience.
18:55Immunology, oncology, virology, neurosciences, ophthalmology and aesthetic medicine.
19:02We are present in more than 70 countries with about 47,000 employees.
19:07In general, AbbVie's research commitment in 2024 was equal to about 13 billion dollars,
19:15which represents an increase of 66.66% compared to the commitment of 2023.
19:21In our country, this company is carrying out 78 clinical studies
19:25involving about 400 experimental centers.
19:28In Italy, AbbVie's history is long.
19:31We have been present since 1949 with Abbott.
19:34AbbVie was born in 2013 as an Abbott spin-off
19:39and today has about 1,700 employees in Italy.
19:43Half of these employees are involved in the Campoverde productive hub,
19:47which represents a flagship for us.
19:49The company has invested a lot in the Campoverde hub
19:54to bring it to very high standards of competitiveness and environmental sustainability.
19:59These standards have allowed us to bring to our country
20:02the production of many active pharmaceuticals that AbbVie makes available to the world.
20:13Cardiovascular events are the first cause of death in the world.
20:17It is therefore essential, in terms of prevention and risk containment,
20:21to know all the factors that negatively impact cardiovascular health.
20:25Hypertension, hypercholesterolemia, diabetes, cigarette smoke,
20:29high levels of lipoprotein A are also added,
20:32a subtype of lipoprotein responsible for the transport of cholesterol into the circulatory system.
20:38Note also how LPA, in the presence of other risk factors
20:41and in concentrations higher than 50 mg per deciliter,
20:45exponentially increases the cardiovascular risk level of the subject.
20:49Lipoprotein A is today another risk factor
20:53that has been categorized as an independent risk factor compared to others,
20:57but in addition to being independent,
20:59it also has the ability to worsen the risk of the patient
21:03who normally presents other risk factors.
21:06To explain it better, if a patient has hypercholesterolemia, hypertension,
21:11and therefore enters a moderate risk category,
21:13if he has high levels of lipoprotein A,
21:16this puts him in a higher risk category,
21:19that is, he becomes a high risk instead of a moderate risk.
21:22But what is this lipoprotein A?
21:24Lipoprotein A is nothing more than a component of LDL
21:27and it is a component that makes that LDL even worse.
21:30That is, already the base LDL is atherogenous,
21:32with lipoprotein A we identify that LDL that is even more atherogenous,
21:36that goes even more easily to attack our bases.
21:39Lipoprotein A is very simple to test,
21:42with a normal, classic blood test,
21:45and above all it is genetically determined,
21:47so it is enough to measure it only once in the life of a subject
21:51and we already have a fairly significant estimate of its value,
21:54with small oscillations in the field of life.
21:56Today the only therapeutic option able to significantly reduce
22:00the levels of lipoprotein A is plasmatherapy.
22:03Fortunately, however, new molecules are being studied,
22:06whose potential to reduce the levels of this lipoprotein
22:09seems to be equal or even higher than 80%.
22:13Until now we did not have really effective pharmacological instruments.
22:18At the best we were able to lower the levels by about 30%.
22:22Currently two types of molecules are being studied,
22:26they are all molecules that silence the gene,
22:29that is, they block the production of this lipoprotein A.
22:33The media tutorial, not only LDL cholesterol,
22:36at the discovery of lipoprotein A,
22:38held in Milan, is promoted by Novartis,
22:40committed to research and development of new therapeutic solutions
22:44in the cardiovascular area for more than 40 years.
22:47Science has allowed us to understand some prognostic and predictive factors
22:52on which to work with therapeutic solutions
22:55that we are researching and developing
22:58to reduce the risk of cardiovascular events.
23:01They remain the first cause of death in Italy, in Europe and in the world.
23:06And this is what pushes us not to stop.
23:09Our goal and our ambition is that
23:12no heart stops beating too soon.
23:16And to achieve this goal,
23:19we continue in research and development
23:22of innovative therapeutic solutions for patients.
23:31The Italian Pharmaceutical Agency has approved
23:33the reimbursement of Lilly's tirzepatide,
23:35the first and only drug of a new therapeutic class
23:39with a GIP and GLP-1 receptor.
23:42The drug, inserted in note 100,
23:44can be prescribed by specialists and by doctors of general medicine.
23:48It is the concrete answer to the needs of patients affected by diabetes
23:51and specialists,
23:53arrived by the therapeutic innovation,
23:55as the diabetic disease is common, chronic, complex and expensive
23:59for those who cure and those who are cured.
24:0190% of diagnosed cases are represented by type 2,
24:06increasing all over the world.
24:08The management of this disease is difficult
24:10and many patients' needs remain unsatisfied.
24:14Only one in two people with type 2 diabetes, in fact,
24:17reaches the target of 6.5-7% of the glycated hemoglobin,
24:22the reference parameter,
24:24which indicates whether diabetes is well compensated over time.
24:27This is often linked to a delayed diagnosis,
24:30to the non-tempestuous use of drugs
24:33that can change the natural history of the disease,
24:36but also to the difficulty of managing
24:38in the daily life of the person,
24:40which translates into reduced adherence to the use of drugs.
24:45Therefore, new therapeutic opportunities are welcome,
24:48which are able to significantly impact on all these aspects
24:52and therefore allow us to cure this pathology at best,
24:56which has a strong clinical impact on the quality of life,
25:00but also on the sustainability of our national health system.
25:04Diabetes, as a chronic disease,
25:06involves an increased risk of complications of the vascular nature,
25:10which involve several organs.
25:12This is why in the management of patients
25:14it is important to adopt a multidisciplinary approach.
25:17The commitment must be that,
25:19not only to ensure, obviously,
25:21competent specialists in this specific territory,
25:24which is that of diabetology,
25:26therefore an oculist who knows the complications of diabetes,
25:29but the problem is to make sure
25:31that the specialist reaches the patient,
25:34sees the patient at the right time,
25:36not too late,
25:37when the complications are already advanced,
25:40and this is an organizational issue
25:42that is not always so simple to deal with and solve.
25:47Lilia has always been a protagonist in the fight against diabetes
25:50thanks to a constant commitment to research
25:52and the development of innovative therapies,
25:54a commitment that today is renewed with Tirzahepatide.
25:58A product completely made in Italy,
26:00we are proud to produce it in our plant in Sesto Fiorentino,
26:05through an expansion that has guaranteed an investment in Italy
26:09of about one billion euros,
26:11a product that is exported to more than 70 countries around the world,
26:15a product that today is available in all regions of Italy
26:19and the shelves from Sesto Fiorentino
26:22are dressed with the Italian flag,
26:24so a double reason for pride for us as a company,
26:27but above all a great opportunity for patients
26:29and for the system as a whole.
26:31What is NutriPiatto?
26:36Not only a theoretical project,
26:38but a real practical tool that guides parents, teachers and children
26:42in the preparation of balanced meals
26:44through a clear and engaging methodology.
26:47NutriPiatto is the nutritional education program
26:50carried out by Gruppo Nestre
26:52with the scientific contribution of the Università Campus Biomedico di Roma
26:55and the Italian Society of Preventive and Social Pediatrics
26:58that teaches children from 4 to 12 years old to their families
27:02how to build balanced meals,
27:04whose results have been presented to the Ministry of Education and Merit.
27:08Thanks to an innovative approach based on interactive educational materials,
27:12educational cards and educational activities,
27:15the project has already reached thousands of families and schools throughout Italy.
27:18It has been presented from 2019 to today
27:22to about 500,000 children in schools
27:26contributing in this way to inform
27:29and improve the knowledge of them and their families
27:32about good nutritional education.
27:34In promoting a correct diet,
27:36companies have a double role.
27:39First, to continue to improve with scientific research and innovation
27:43the quality of their products,
27:45in order to make them more and more suitable for today's food challenges.
27:48And then they also have the role of being active in communication,
27:51in the dissemination and information of good practices
27:55and correct eating habits,
27:58which we have been doing for years in collaboration with these scientific entities
28:03and with the help of the Ministry of Education and Merit for access to schools.
28:11This was our latest news.
28:13To contact us, you can write to salutechiocciola at dnchronos.com.
28:17Thank you for following us and see you next time.
28:21www.dnchronos.com